Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY January 2024 slide deck - over 120 panc pts studied

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Feb 05, 2024 1:18pm

414 Views

Post# 35863423

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

Oh boy....you went and added these up. Man, you got issues. Yes, you post a lot of facts none of which guarantee anything. Your recent redundancy concentrating on naming names and reposting of successful Pela achievements and big Pharma buyouts makes you look desperate. Take a chill pill. I do not mean to chide you but your take on people and other things just might be inacurrate. Why don't you deal with that. Off to the gym

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland